Citations to this article
Citation Information: JCI Insight. 2018;3(8):e99488. https://doi.org/10.1172/jci.insight.99488.
Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model
Abstract
T cell receptor (TCR) T cell therapy is a promising cancer treatment modality. However, its successful development for epithelial cancers may depend on the identification of high-avidity TCRs directed against tumor-restricted target antigens. The human papillomavirus (HPV) E7 antigen is an attractive therapeutic target that is constitutively expressed by HPV+ cancers but not by healthy tissues. It is unknown if genetically engineered TCR T cells that target E7 can mediate regression of HPV+ cancers. We identified an HPV-16 E7-specific, HLA-A*02:01-restricted TCR from a uterine cervix biopsy from a woman with cervical intraepithelial neoplasia. This TCR demonstrated high functional avidity, with CD8 coreceptor–independent tumor targeting. Human T cells transduced to express the TCR specifically recognized and killed HPV-16+ cervical and oropharyngeal cancer cell lines and mediated regression of established HPV-16+ human cervical cancer tumors in a mouse model. These findings support the therapeutic potential of this approach and established the basis for an E7 TCR gene therapy clinical trial in patients with metastatic HPV+ cancers (NCT02858310).
Authors
Benjamin Y. Jin, Tracy E. Campbell, Lindsey M. Draper, Sanja Stevanović, Bianca Weissbrich, Zhiya Yu, Nicholas P. Restifo, Steven A. Rosenberg, Cornelia L. Trimble, Christian S. Hinrichs
Total citations by year
Citations to this article in year 2021 (18)
| Title and authors | Publication | Year |
|---|---|---|
|
Induction of EBV latent membrane protein-2A (LMP2A)-specific T cells and construction of individualized TCR-engineered T cells for EBV-associated malignancies
C Zhang, Q Tan, S Li, L Shen, J Zhang, Y Liu, W Yang, Z Lu |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Chimeric antigen receptor engineered NK cellular immunotherapy overcomes the selection of T-cell escape variant cancer cells
MY Lee, Y Robbins, C Sievers, J Friedman, HA Sater, PE Clavijo, N Judd, E Tsong, C Silvin, P Soon-Shiong, MR Padget, J Schlom, J Hodge, C Hinrichs, C Allen |
Journal for ImmunoTherapy of Cancer | 2021 |
|
Immunotherapy for HPV Malignancies
MY Lee, CT Allen |
Seminars in radiation oncology | 2021 |
|
Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives
Y Tang, AX Zhang, G Chen, Y Wu, W Gu |
Molecular Therapy — Oncolytics | 2021 |
|
Engineered TCR-T Cell Immunotherapy in Anticancer Precision Medicine: Pros and Cons
Q Zhao, Y Jiang, S Xiang, PJ Kaboli, J Shen, Y Zhao, X Wu, F Du, M Li, CH Cho, J Li, Q Wen, T Liu, T Yi, Z Xiao |
Frontiers in immunology | 2021 |
|
Preclinical study of a novel therapeutic vaccine for recurrent respiratory papillomatosis
MY Lee, S Metenou, DE Brough, H Sabzevari, K Bai, C Jochems, J Schlom, CT Allen |
npj Vaccines | 2021 |
|
T cells targeted to TdT kill leukemic lymphoblasts while sparing normal lymphocytes
M Ali, E Giannakopoulou, Y Li, M Lehander, SV Culleton, W Yang, C Knetter, MC Odabasi, RC Bollineni, X Yang, Z Foldvari, ML Böschen, E Taraldsrud, E Strønen, M Toebes, A Hillen, S Mazzi, AH de Ru, GM Janssen, A Kolstad, GE Tjønnfjord, BA Lie, M Griffioen, S Lehmann, LT Osnes, J Buechner, KC Garcia, TN Schumacher, PA van Veelen, M Leisegang, SE Jacobsen, P Woll, J Olweus |
Nature Biotechnology | 2021 |
|
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
Y Xu, J Jiang, Y Wang, W Wang, H Li, W Lai, Z Zhou, W Zhu, Z Xiang, Z Wang, Z Zhu, L Yu, X Huang, H Zheng, S Wu |
Frontiers in immunology | 2021 |
|
Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers
X Wang, ML Sandberg, AD Martin, KR Negri, GB Gabrelow, DP Nampe, ML Wu, ME McElvain, DT Warshaviak, WH Lee, J Oh, ME Daris, F Chai, C Yao, J Furney, C Pigott, A Kamb, H Xu |
Journal of immunotherapy (Hagerstown, Md. : 1997) | 2021 |
|
T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy
Z Duan, M Ho |
Molecular cancer therapeutics | 2021 |
|
An efficient method to identify virus-specific TCRs for TCR-T cell immunotherapy against virus-associated malignancies
L Chen, L Dong, Y Ma, J Wang, D Qiao, G Tian, M Wang |
BMC Immunology | 2021 |
|
Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic
X Zhang, M Luo, SR Dastagir, M Nixon, A Khamhoung, A Schmidt, A Lee, N Subbiah, DC McLaughlin, CL Moore, M Gribble, N Bayhi, V Amin, R Pepi, S Pawar, TJ Lyford, V Soman, J Mellen, CL Carpenter, LA Turka, TJ Wickham, TF Chen |
Nature Communications | 2021 |
|
Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants
C Hu, M Shen, X Han, Q Chen, L Li, S Chen, J Zhang, F Gao, W Wang, Y Wang, T Li, S Li, J Huang, J Wang, J Zhu, D Chen, Q Wu, K Tao, D Pang, A Jin |
Genes & Diseases | 2021 |
|
SARS‐CoV‐2‐reactive T‐cell receptors isolated from convalescent COVID‐19 patients confer potent T‐cell effector function
F Brunk, A Moritz, A Nelde, T Bilich, N Casadei, SA Fraschka, JS Heitmann, S Hörber, A Peter, HG Rammensee, H Singh, J Walz, D Maurer, C Wagner |
European Journal of Immunology | 2021 |
|
CD8+ T Cell Exhaustion in Cancer
JS Dolina, NV Braeckel-Budimir, GD Thomas, S Salek-Ardakani |
Frontiers in immunology | 2021 |
|
Immunotherapy Approaches in HPV-Associated Head and Neck Cancer
R Julian, M Savani, JE Bauman |
Cancers | 2021 |
|
Ultrasonic Elastography Combined with Human Papilloma Virus Detection Based on Intelligent Denoising Algorithm in Diagnosis of Cervical Intraepithelial Neoplasia
L Sun, X Shan, Q Dong, C Wu, M Shan, H Guo, R Lu, O Khalaf |
Computational and mathematical methods in medicine | 2021 |
|
TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers
Nagarsheth NB, Norberg SM, Sinkoe AL, Adhikary S, Meyer TJ, Lack JB, Warner AC, Schweitzer C, Doran SL, Korrapati S, Stevanović S, Trimble CL, Kanakry JA, Bagheri MH, Ferraro E, Astrow SH, Bot A, Faquin WC, Stroncek D, Gkitsas N, Highfill S, Hinrichs CS |
Nature Medicine | 2021 |
